Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung
Saijo, N.; Shimizu, E.; Eguchi, K.; Shinkai, T.; Tominaga, K.; Shibuya, M.; Shimabukuro, Z.; Niitani, H.; Hoshi, A.
Cancer Treatment Reports 67(4): 385-387
1983
ISSN/ISBN: 0361-5960 PMID: 6189601 Document Number: 197702
The effects of two chemotherapeutic regimens, peplomycin (PLM) plus carbazilquinone and PLM plus mitomycin, on non-small cell carcinoma of the lung were evaluated by a randomized controlled trial. Seven partial responses were observed in 53 evaluable patients, for an overall response rate of 13.2%. There was no difference in response rate or in median survival time between PLM plus carbazilquinone (11.5% and 32 weeks) and PLM plus mitomycin (14.8% and 25 weeks). Seven patients developed interstitial pneumonitis, and four died of pulmonary fibrosis. It was concluded that the chemotherapeutic regimens that include PLM are only marginally effective against non-small cell carcinoma of the lung, with relatively frequent pulmonary fibrosis.